Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Devyser Diagnostics AB (FRA:OL0) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Devyser Diagnostics AB EBITDA Margin % Related Terms
Devyser Diagnostics AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Devyser Diagnostics AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OL0 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Devyser Diagnostics AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devyser Diagnostics AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Devyser Diagnostics AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Devyser Diagnostics AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devyser Diagnostics AB (FRA:OL0) has a EBITDA Margin % of 16.28% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Devyser Diagnostics AB and its competitors. According to the industry distribution chart, Devyser Diagnostics AB ranks #169 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 20.7%.
Is Devyser Diagnostics AB's EBITDA Margin % too high?
Devyser Diagnostics AB's current EBITDA Margin % is 16.28%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.59. Devyser Diagnostics AB's value of 16.28% is 114.5% above this industry median. Based on the distribution chart, Devyser Diagnostics AB ranks #169 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Devyser Diagnostics AB has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Devyser Diagnostics AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Devyser Diagnostics AB ranks #169 out of 816 companies for EBITDA Margin %. This places Devyser Diagnostics AB in the top 21% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.59. Devyser Diagnostics AB's value of 16.28% is 114.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.59, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Devyser Diagnostics AB's current EBITDA Margin % of 16.28% is 114.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Devyser Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Devyser Diagnostics AB's current EBITDA Margin % is 16.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devyser Diagnostics AB stock overvalued right now?
Devyser Diagnostics AB (FRA:OL0) has a current EBITDA Margin % of 16.28%. The stock's GF Value™ is €11.96, compared to a current price of €5.90 — trading 50.7% below its estimated fair value. The current EBITDA Margin % is 16.28% and 114.5% above the Medical Devices & Instruments industry median of 7.59. Devyser Diagnostics AB's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Devyser Diagnostics AB (FRA:OL0), the current EBITDA Margin % is 16.28% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devyser Diagnostics AB (FRA:OL0) Overvalued in 2026?
Based on GuruFocus' analysis, Devyser Diagnostics AB stock appears to be undervalued.
The current stock price of €5.90 is trading 50.7% below its estimated GF Value™ of €11.96.
Key valuation signals for FRA:OL0:
EBITDA Margin %: 16.28%
GF Value™: €11.96 vs. price of €5.90 (50.7% below fair value)
Industry Position: 114.5% above the Medical Devices & Instruments median (#169 of 816)
No single metric tells the full story. See the FRA:OL0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devyser Diagnostics AB is engaged in the development, manufacture, and sale of kits for genetic testing in routine diagnostic laboratories. The products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.
68GF Score
Get the complete analysis for FRA:OL0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OL0 has been successfully added to your 
